Organization
Robert H. Lurie Comprehensive Cancer Center, Northwestern University
26 abstracts
2 posters
Abstract
A phase 1 study of the protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor PRT811 in patients (pts) with recurrent high-grade glioma or uveal melanoma (UM).Org: Prelude Therapeutics Incorporated, Washington University School of Medicine, Sarah Cannon Research Institute at HealthONE, Florida Cancer Specialists/Sarah Cannon Research Institute, Prelude Therapeutics, Inc.,
Abstract
Phase II study of a PARP inhibitor, talazoparib, in HER2- metastatic breast cancer (MBC) with a somatic BRCA1/2 mutation identified in a cell-free DNA or tumor tissue genotyping assay.Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, The University of Texas MD Anderson Cancer Center, Emory University School of Medicine, Massachusetts General Hospital,
Abstract
Cost-effectiveness of a circulating tumor fraction molecular biomarker for treatment response monitoring.Org: Tempus AI, Perelman School of Medicine at the University of Pennsylvania, Abramson Cancer Center, Ochsner Health Center, Johns Hopkins University,
Abstract
Impact of clinical response and AEs on health-related quality of life (HRQoL) in patients (pts) with R/R large B-cell lymphoma (LBCL): Pooled data from 4 lisocabtagene maraleucel (liso-cel) trials.Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, Evidera PPD, Bethesda, Bristol Myers Squibb,
Abstract
Association of symptom severity, anxiety, and health literacy with portal usage among patients with cancer.Org: Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Northwestern University, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Department of Medical Social Sciences,
Abstract
Relationship between dynamic changes in circulating tumor fraction and real-world imaging with real-world survival in patients with solid tumors treated with immunotherapy.Org: Tempus AI, Tempus Labs, Inc., Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Washington University School of Medicine in St. Louis,
Abstract
Clinical, environmental, genetic, and genomic profile of men with early-onset aggressive prostate cancer: A final report.Org: Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Dana-Farber Cancer Institute, Michigan Medicine, Rogel Cancer Center, University of Michigan, Ann Arbor, MI,
Abstract
Comparing rates of immune checkpoint inhibitor toxicity in different treatment settings (neoadjuvant, adjuvant, and palliative) in non-small cell lung cancer (NSCLC): A meta-analysis of phase III clinical trials.Org: Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Northwestern University Feinberg School of Medicine, Northwestern Memorial Hospital, Chicago, IL, John H. Stroger, Jr. Hospital of Cook County,
Abstract
Predictive factors for cardiac events following concurrent chemotherapy and radiation with durvalumab consolidation for unresectable non-metastatic non-small cell lung cancer.Org: Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Biostatistics, Indiana University School of Medicine, Indianapolis, IN, Feinberg School of Medicine,
Abstract
Surgical window of opportunity clinical trial of abemaciclib and letrozole for endometrioid adenocarcinoma of the endometrium.Org: Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China, Northwestern Memorial Hospital, Chicago, IL, Chicago, IL, Il-Yang Pharmaceuticals, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center,
Abstract
Double lung transplantation in patients with recent history of malignancy.Org: Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Northwestern University Feinberg School of Medicine, Chicago, IL, Feinberg School of Medicine,
Abstract
Prognostic value of tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer (BC): A focus on inflammatory BC.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Northwestern University, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Washington University in St. Louis,
Abstract
The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP.Org: Mount Sinai Health System, SWOG Statistics and Data Management Center, Seattle, WA, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Dana-Farber Cancer Institute, SWOG Statistical Center,
Abstract
ESR1 mutational landscape and impact of co-existing resistance variants on clinical outcomes in patients with metastatic breast cancer.Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Harvard Medical School, Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, Guardant Health, Inc., Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,
Abstract
Homologous recombination deficiency (HRD) in non-small cell lung cancer: Genomic analysis using an RNA-based HRD algorithm.Org: Tempus Labs, Inc., University of Pennsylvania, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center,
Abstract
Phase II study of a PARP inhibitor in somatic BRCA1/2 mutant metastatic breast cancer (MBC).Org: Harvard Medical School, Massachusetts General Hospital, Boston, MA, MD Anderson Cancer Center, Houston, TX,
Abstract
Multi-factor dynamic analysis of ctDNA and CTC to aid the diagnostic prognosis of patients with metastatic breast cancer (MBC).Org: Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, CTC Core Facility, Lurie Cancer Center,
Abstract
Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment.Org: Medical College of Wisconsin, Milwaukee, WI, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland, IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli” and Dipartimento di Medicina Specialistica,
Abstract
Prostate-specific antigen value at 3 & 7 months (PSA-3mo, PSA-7mo) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation (ADT) with or without orteronel (SWOG S1216).Org: University of California Davis Comprehensive Cancer Center, SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Cleveland Clinic Taussig Cancer Instititute,
Abstract
Ibrutinib dose modifications for management of cardiac adverse events in patients with B-cell malignancies: Pooled analysis of 10 clinical trials.Org: Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, CLL Center, Dana-Farber Cancer Institute,
Abstract
First results from the RETgistry: A global consortium for the study of resistance to RET inhibition in RET-altered solid tumors.Org: Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Lombardi Comprehensive Cancer Center, University of Berne and Cantonal Hospital of Lucerne,
Abstract
Epidemiologic effectors on the breast tumor microenvironment: Results from the Cancer Prevention Study-II and -3 cohorts.Org: John H. Stroger, Jr. Hospital of Cook County, Northwestern University Feinberg School of Medicine, American Cancer Society, National Cancer Institute, Vilnius, Lithuania, Robert H. Lurie Comprehensive Cancer Center, Northwestern University,
Abstract
Evaluation of cachexia and outcomes in patients with aggressive B-cell non-Hodgkin lymphoma.Org: Feinberg School of Medicine, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Shirley Ryan AbilityLab,
Abstract
Dares: A phase II trial of durvalumab and ablative radiation in extensive stage small cell lung cancer.Org: University of Chicago Medical Center, Chicago, IL, University of Kansas Medical Center, Department of Biostatistics & Data Science, University of Kansas Medical Center (KUMC), Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, University of Chicago,
Abstract
Retrospective analysis of NUT carcinoma: The Northwestern experience.Org: Northwestern Medicine Cancer Center Warrenville, Northwestern University-Feinberg School of Medicine, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Robert H. Lurie Comprehensive Cancer Center, Northwestern University,
Abstract
RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non–small cell lung cancer (NSCLC).Org: Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Washington, DC, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, Lecanto, FL,